ArticleOncogene2022

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.

Hiroshi Ikeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.